A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma

被引：0
|
作者：
Tulpule, A [1 ]
Khan, AU [1 ]
Mohrbacher, AF [1 ]
Espina, BM [1 ]
Buchanan, L [1 ]
Berman, N [1 ]
Gorospe, G [1 ]
Boswell, WD [1 ]
Nathwani, BN [1 ]
Levine, AM [1 ]
机构：
[1] USC, Keck Sch Med, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6688
引用
收藏
页码：604S / 604S
页数：1
相关论文
共 50 条
  • [1] A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma.
    Tulpule, A
    Duran, CA
    Smith, DL
    Berman, NE
    Buchanan, L
    Gorospe, G
    Boswell, W
    Nathwani, B
    Levine, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 593S - 593S
  • [2] Preliminary results of a phase II trial of pegylated liposomal doxorubicin (Doxil), rituxan, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma.
    Tulpule, A
    Khan, AU
    Mohrbacher, A
    Weitz, IC
    Espina, BM
    Boswell, WD
    Nathwani, BN
    Levine, AM
    BLOOD, 2003, 102 (11) : 286B - 286B
  • [3] A phase II trial of pegylated doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in patients with newly diagnosed AIDS-associated B-cell non-Hodgkin's lymphoma (ARL): An AIDS Malignancy Consortium trial (AMC 047)
    Levine, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide,vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma
    Tulpule, Anil
    Espina, Byron M.
    Berman, Nancy
    Buchanan, Laura H.
    Smith, D. Lynne
    Sherrod, Andy
    Dharmapala, Dharshika
    Gee, Conway
    Boswell, William D.
    Nathwani, Bharat N.
    Welles, Lauri
    Levine, Alexandra M.
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (01) : 59 - 64
  • [5] Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: Study of 26 patients
    Moreno, Miriam
    Sancho, Juan-Manuel
    Gardella, Santiago
    Coll, Rosa
    Garcia, Olga
    Gallardo, David
    Ribera, Josep-Maria
    MEDICINA CLINICA, 2010, 134 (02): : 72 - 75
  • [6] Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma
    Gao, Yuhuan
    Xie, Yan
    Liu, Lihong
    Xue, Hongwei
    Hou, Ming
    Zhang, Mingzhi
    Zhou, Zeping
    Guo, Pengxiang
    Yao, Hongxia
    Shao, Zonghong
    Xie, Xiaobao
    Zhu, Jun
    MINERVA MEDICA, 2021, 112 (02) : 310 - 312
  • [7] A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin's Lymphoma
    Cohen, Jonathon B.
    Switchenko, Jeffrey
    Koff, Jean L.
    Sinha, Rajni
    Kaufman, Jonathan L.
    Khoury, H. Jean
    Bumpers, Nassoma K.
    Colbert, Amanda
    Hutchison-Rzepka, Amanda A.
    Nastoupil, Loretta J.
    Heffner, Leonard T.
    Langston, Amelia
    Lechowicz, Mary Jo
    Lonial, Sagar
    Flowers, Christopher R.
    BLOOD, 2014, 124 (21)
  • [8] Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma
    Visani, G
    Guiducci, B
    D'Adamo, F
    Mele, A
    Nicolini, G
    Leopardi, G
    Sparaventi, G
    Barulli, S
    Malerba, L
    Isidori, A
    Malagola, M
    Piccaluga, PP
    LEUKEMIA & LYMPHOMA, 2005, 46 (03) : 477 - 479
  • [9] Combined therapy with rituximab plus cyclophosphamide/Vincristine/Prednisone for Sjogren's syndrome - associated B-Cell non-Hodgkin's lymphoma
    Carbone, J.
    Perez-Fernandez, R.
    Munoz, A.
    Sabin, P.
    Carreno, L.
    Fernandez-Cruz, E.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2008, 34 (01) : 80 - 84
  • [10] Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas
    Voulgarelis, M
    Giannouli, S
    Anagnostou, D
    Tzioufas, AG
    RHEUMATOLOGY, 2004, 43 (08) : 1050 - 1053
12345